<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6878F160-3C35-4AC6-8D56-FBD6D6FB37B4"><gtr:id>6878F160-3C35-4AC6-8D56-FBD6D6FB37B4</gtr:id><gtr:name>Amgen Inc</gtr:name><gtr:address><gtr:line1>One Amgen Center Drive</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FAE32A25-51D3-49EF-998F-281B3A47C212"><gtr:id>FAE32A25-51D3-49EF-998F-281B3A47C212</gtr:id><gtr:name>Helmholtz Association of German Research Centres</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:department>William Harvey Research Institute</gtr:department><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6878F160-3C35-4AC6-8D56-FBD6D6FB37B4"><gtr:id>6878F160-3C35-4AC6-8D56-FBD6D6FB37B4</gtr:id><gtr:name>Amgen Inc</gtr:name><gtr:address><gtr:line1>One Amgen Center Drive</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FAE32A25-51D3-49EF-998F-281B3A47C212"><gtr:id>FAE32A25-51D3-49EF-998F-281B3A47C212</gtr:id><gtr:name>Helmholtz Association of German Research Centres</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/903257E2-160F-404D-AC00-05529B751068"><gtr:id>903257E2-160F-404D-AC00-05529B751068</gtr:id><gtr:firstName>Yuti</gtr:firstName><gtr:surname>Chernajovsky</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DDD51DE8-1007-4BA6-B390-41A4B5B4F076"><gtr:id>DDD51DE8-1007-4BA6-B390-41A4B5B4F076</gtr:id><gtr:firstName>Gillian</gtr:firstName><gtr:surname>Adams</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0800795"><gtr:id>EA56535C-62D8-4CD6-8A9D-3C38E96CA4AD</gtr:id><gtr:title>Towards a targeted therapy for arthritis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0800795</gtr:grantReference><gtr:abstractText>We have developed a new drug delivery technology that allows the drug to be protected from being degraded in the body and targets it to the site of disease. The drug delivery system is composed of a shell derived from a naturally occurring molecule called latency associated peptide (LAP). LAP forms a shell around the drug and is therefore protecting the drug from degradation within the body. The shell is opened through an enzyme-sensitive cleavage site. The enzymes that can open the shell are found at sites of inflammation particularly in joints affected by arthritis. The shell is therefore only opened and it?s contents released at the sites of disease.
This technology has many advantages over current biological drugs as it targets the release of the drug only to sites of disease thus preventing side effects, and the drug can be used in small doses. In this study we will produce and purify sufficient material of different forms of the shell and drug that can be tested, pharmaceutically assessed, and compared in a model of arthritis. In this way, we will obtain data that is essential to allow us bring this novel technology to clinical trials in humans. The success of this project will enable us to expand the use of this technology to other diseases that have a destructive/inflammatory component such as Crohn?s disease, multiple sclerosis and atherosclerosis.</gtr:abstractText><gtr:technicalSummary>To enable targeting of cytokines and other therapeutic molecules to sites of disease, we have developed a novel platform technology that harnesses the pathological process to release the therapeutic moiety in situ and provides for longer half-life. We built a stable ?shell? by fusing the latency associated peptide precursor part of transforming growth factor beta, through a linker with a matrix metalloproteinase- or aggrecanase-sensitive site (thus targeting release/activation to inflammatory sites) to a therapeutic cytokine (IFN beta) for arthritis treatment. In this study we will express and biochemically purify sufficient recombinant protein to provide data on pharmacokinetics, pharmacodynamics, immunogenicity, toxicology and therapeutic efficacy in an arthritis model. This work is essential to produce preclinical data and bring this technology to the level of a phase I/II clinical trial.</gtr:technicalSummary><gtr:fund><gtr:end>2012-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>367189</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Amgen Inc</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Crystal structure of LAP-IL-10</gtr:description><gtr:id>6DD9BE80-F252-4316-85F2-4EBE632D16DE</gtr:id><gtr:impact>NA</gtr:impact><gtr:outcomeId>UayT7Qx46F9-1</gtr:outcomeId><gtr:partnerContribution>I spend a mini sabbatical at Amgen in Seattle (3 months) that as a result this collaboration was set up</gtr:partnerContribution><gtr:piContribution>We are expressing LAp-IL-10 in a baculovirus system with a view to crystalise and define its structure with colleagues at Birbeck College. This study is funded by Amgen Corp. USA</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Helmholtz Association of German Research Centres</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Helmholtz Centre for Infection Research (HZI)</gtr:department><gtr:description>In vivo real time pharmacodynamic imaging using a transgenic mouse</gtr:description><gtr:id>ADD64F73-E2CD-4182-B400-3E580C88FA90</gtr:id><gtr:impact>na</gtr:impact><gtr:outcomeId>YoEJ47JMCun-1</gtr:outcomeId><gtr:partnerContribution>this is allowing us to measure in real time delivery of LAP-IFN constructs to sites of disease</gtr:partnerContribution><gtr:piContribution>We are starting to image these Mx2-luciferase Tg mice after administration of IFN beta followed by luciferin substrate and imaging the PK/PD</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>103000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>project grant</gtr:description><gtr:end>2011-06-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:fundingRef>PG/09/093</gtr:fundingRef><gtr:id>5F8C7E96-9D5F-4A53-B2A3-ECB27A872A58</gtr:id><gtr:outcomeId>ht86mqTSB4L0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>213000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>project grant</gtr:description><gtr:end>2013-02-02</gtr:end><gtr:fundingOrg>Breast Cancer Campaign (BCC)</gtr:fundingOrg><gtr:id>A65A22D3-C172-4411-BD4B-5FF6686EC4D6</gtr:id><gtr:outcomeId>VCmjGfTyMeW0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>We have designed a method of closing the LAP shell enabling the delivery of antibody fragments and soluble cytokine receptors in a latent form to sites of disease where they get released through cleavage by matrix metalloproteinases.</gtr:description><gtr:grantRef>G0800795</gtr:grantRef><gtr:id>E2BBA0E9-E0B6-4B2A-99BC-2134AF5D9471</gtr:id><gtr:impact>see above</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>56b2f4396539f0.17131791</gtr:outcomeId><gtr:patentId>PCT WO 2015/198072 A1</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Modified Latency Associated Protein Construct</gtr:title><gtr:yearProtectionGranted>2015</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The discovery describes a cytokine delivery technology that targets delivery to sites high in aggrecanase activity such as the arthritic joint</gtr:description><gtr:grantRef>G0800795</gtr:grantRef><gtr:id>236922F4-3EC8-4C20-A749-E5FA1E38F4BD</gtr:id><gtr:impact>N/A</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>CDoAtPmbZrE</gtr:outcomeId><gtr:patentId>US2010310515</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Latency associated protein construct with aggrecanase-sensitive cleavage site</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>CHO expressed glycosylated material with murine sequences in various isoforms for testing in vivo</gtr:description><gtr:id>81DD2C8A-83B6-488F-AE2C-86A395852822</gtr:id><gtr:impact>Better PK data expected than originally planned in original application</gtr:impact><gtr:outcomeId>70C0F5D97D5</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>mouse LAP-IFN beta</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>This material is cleaved specifically by aggreacanase and synovila fluid from osteoarthritic patients</gtr:description><gtr:id>7865F81E-02B0-4E6F-8E58-E93BE4ABB6E4</gtr:id><gtr:impact>This material has shown better therapeutic efficacy in a collagen-induced arthritis model than that obtained with a MMP cleavable fusion protein</gtr:impact><gtr:outcomeId>DWgiDv1KiYF</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>mLAP-aggrecanase-IFN beta</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>77ECA703-2337-4EA4-8676-59F6DB183399</gtr:id><gtr:title>A comparative study of matrix metalloproteinase and aggrecanase mediated release of latent cytokines at arthritic joints.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b79f88b1ac3fd079f39442a7b160e01"><gtr:id>9b79f88b1ac3fd079f39442a7b160e01</gtr:id><gtr:otherNames>Mullen L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>b42au8dhWvG</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17172F08-76BA-4035-A7D8-3806B4E3F378</gtr:id><gtr:title>Increased disulphide dimer formation of latent associated peptide fusions of TGF-? by addition of L-cystine.</gtr:title><gtr:parentPublicationTitle>Journal of biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d1ba876be331a47a437c0111a0602fe"><gtr:id>9d1ba876be331a47a437c0111a0602fe</gtr:id><gtr:otherNames>Mullen LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0168-1656</gtr:issn><gtr:outcomeId>pm_12853_23_22835852</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C7BA2E95-11D4-4FFD-98ED-5C26D76CB5EE</gtr:id><gtr:title>Latency can be conferred to a variety of cytokines by fusion with latency-associated peptide from TGF-?.</gtr:title><gtr:parentPublicationTitle>Expert opinion on drug delivery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b79f88b1ac3fd079f39442a7b160e01"><gtr:id>9b79f88b1ac3fd079f39442a7b160e01</gtr:id><gtr:otherNames>Mullen L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1742-5247</gtr:issn><gtr:outcomeId>pm_12853_23_24073618</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC907598-77E3-4FB8-9CBF-7179DFAA02E5</gtr:id><gtr:title>Fusion Protein Technologies for Biopharmaceuticals - Applications and Challenges</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b79f88b1ac3fd079f39442a7b160e01"><gtr:id>9b79f88b1ac3fd079f39442a7b160e01</gtr:id><gtr:otherNames>Mullen L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>56b2f7069c8090.29892844</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74DD0D02-A861-4028-8E56-ED4B9B693CF9</gtr:id><gtr:title>Latent cytokines for targeted therapy of inflammatory disorders.</gtr:title><gtr:parentPublicationTitle>Expert opinion on drug delivery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b79f88b1ac3fd079f39442a7b160e01"><gtr:id>9b79f88b1ac3fd079f39442a7b160e01</gtr:id><gtr:otherNames>Mullen L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1742-5247</gtr:issn><gtr:outcomeId>pm_540e15fe15f50f407</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA436E45-A8D9-4EEE-B37F-90A6DA878C97</gtr:id><gtr:title>Generation of an efficiently secreted, cell penetrating NF-?B inhibitor.</gtr:title><gtr:parentPublicationTitle>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab84aad28c158d3cc5993d94801a0f0b"><gtr:id>ab84aad28c158d3cc5993d94801a0f0b</gtr:id><gtr:otherNames>Koutsokeras A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0892-6638</gtr:issn><gtr:outcomeId>pm_12853_23_24072781</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800795</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>